MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-520c decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 20/October/2014, 6.13 am

Vitamin-based life-extention therapy for Males: ATRA (a derivative of Vitamin-A) increases male longevity via up regulation of its target gene, 20/October/2014, 6.08 am
October 20, 2014
MiRNA-based therapy for Human Cancer: MiRNA-185 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes, 20/October/2014, 6.17 am
October 20, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-520c decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 20/October/2014, 6.13 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance:  It has been shown that decreasing the expression of Tau protein alleviates the pathogenic symptoms-associated with Alzheimer’s disease. This study suggests, for the first time, that MiRNA-520c decreases the phosphorylation of Tau protein and improves the pathological symptoms associated with Tau accumulation. Thus, pharmacological formulations encompassing MiRNA-520c or its activators” can be used to treat patients suffering from Alzheimer’s disease and tauopathies.

* Research cooperation

Comments are closed.